Sources: In surprise pick, Exelixis' Scangos named CEO of Biogen Idec

Both Bloomberg and Reuters are reporting this morning that George Scangos will leave Exelixis to take over the helm at Biogen Idec. Quoting sources, the news wires report that the veteran biotech exec has been tapped to replace James Mullen, who left the company after a long and bruising fight with Wall Street raider Carl Icahn.

The appointment puts a scientist in the CEO's post at Biogen Idec. Scangos got his biology degree at Cornell. The news of Scangos' appointment to the helm of the big biotech, after 14 years running the relatively tiny Exelixis, was met with a mixed response on Wall Street.

"He's a very good dealmaker, but I wouldn't say Exelixis has done the best job at translating science into novel molecules that come to the marketplace," Michael King, an analyst for Wedbush Morgan Securities in New York, tells Bloomberg. "It remains to be seen what he'll do at a company the size of Biogen."

- here's the story from Bloomberg
- and here's the Reuters piece

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.

Danish drugmaker Novo Nordisk is opening up its bleeding disorder trials five months after they were stopped.